Cash and Short Term Investments (Quarterly) Chart

View Cash and Short Term Investments (Quarterly) for RLAY.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash and Short Term Investments (Quarterly) Chart
Start Trial

Historical Cash and Short Term Investments (Quarterly) Data

View and export this data back to 2019. Start Trial.
Date Value
June 30, 2026 910.93M
March 31, 2026 642.06M
December 31, 2025 554.52M
September 30, 2025 596.43M
June 30, 2025 656.78M
March 31, 2025 710.36M
December 31, 2024 781.32M
September 30, 2024 839.61M
June 30, 2024 688.42M
March 31, 2024 749.61M
December 31, 2023 750.09M
September 30, 2023 810.62M
June 30, 2023 871.57M
March 31, 2023 937.80M
Date Value
December 31, 2022 998.92M
September 30, 2022 1.054B
June 30, 2022 837.99M
March 31, 2022 898.18M
December 31, 2021 958.07M
September 30, 2021 616.51M
June 30, 2021 671.22M
March 31, 2021 726.08M
December 31, 2020 678.06M
September 30, 2020 713.47M
June 30, 2020 312.21M
March 31, 2020 334.20M
December 31, 2019 355.82M

Cash and Short Term Investments Definition

Represents the sum of cash and short term investments.

Read full definition.

Cash and Short Term Investments (Quarterly) Range, Past 5 Years

View Cash and Short Term Investments (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash and Short Term Investments (Quarterly) Benchmarks

View Cash and Short Term Investments (Quarterly) Benchmarks
Start Trial
AbbVie, Inc. 6.569B
TG Therapeutics, Inc. 552.25M
Karyopharm Therapeutics, Inc. 65.10M
Krystal Biotech, Inc. 845.63M
Akebia Therapeutics, Inc. 157.26M